Microbiome Therapeutics After Recurrent C. diff: What’s Real, What’s Hype, and What’s Next?

Introduction

Clostridioides difficile infection (CDI) remains one of the most pressing healthcare associated infections in contemporary clinical practice and is recognized as a major antimicrobial resistance threat. According to estimates from the Centers for Disease Control and Prevention, CDI accounts for nearly 500,000 infections annually in the United States and contributes to approximately 29,000 deaths each year. The burden of disease is particularly pronounced among older adults, immunocompromised individuals, and patients with recent or prolonged antibiotic exposure. Despite advances in infection prevention and antimicrobial stewardship, CDI continues to pose significant challenges due to its high recurrence rates and associated morbidity.

A defining feature of CDI is its tendency to recur. Following initial treatment, approximately 20 to 30 percent of patients experience at least one recurrence, and the risk increases substantially with each subsequent episode. Recurrent CDI is associated with a cycle of repeated antibiotic therapy, hospital readmissions, and progressive deterioration in patient quality of life. Clinically, patients often present with persistent diarrhea, abdominal pain, and systemic symptoms, which can lead to dehydration, malnutrition, and in severe cases, complications such as toxic megacolon or sepsis. From a healthcare systems perspective, recurrent disease contributes to increased costs, prolonged hospital stays, and heightened demands on infection control resources.

Conventional treatment strategies for CDI have relied on targeted antibiotic therapy, most commonly oral vancomycin, fidaxomicin, or metronidazole. While these agents are effective in achieving initial clinical resolution, they do not address the underlying disruption of the intestinal microbiome that predisposes patients to recurrence. Repeated antibiotic exposure may further exacerbate dysbiosis, perpetuating a cycle in which pathogenic C. difficile persists while protective commensal organisms remain depleted. As a result, traditional antimicrobial approaches often fail to provide durable remission in patients with recurrent disease.

The pathophysiology of recurrent CDI is closely linked to alterations in the gut microbiome. In a healthy state, a diverse and balanced microbial community confers colonization resistance by inhibiting the growth and toxin production of pathogenic organisms. Antibiotic use disrupts this ecological balance, reducing microbial diversity and impairing key protective functions such as bile acid metabolism, nutrient competition, and immune modulation. This disruption creates an environment that facilitates C. difficile spore germination, colonization, and toxin mediated epithelial injury. Restoration of microbial homeostasis has therefore emerged as a central therapeutic objective in the management of recurrent CDI.

Microbiome based therapeutics represent a significant shift in treatment strategy, focusing on the reconstitution of a functional microbial ecosystem rather than the eradication of a single pathogen. Early approaches centered on fecal microbiota transplantation, which involves the transfer of stool from a healthy donor to a recipient with CDI. This intervention has demonstrated high efficacy in resolving recurrent infection, with cure rates exceeding those of standard antibiotic regimens in many studies. However, variability in donor material, concerns regarding pathogen transmission, and logistical challenges have limited its widespread standardization in clinical practice.

In response, the field has evolved toward the development of defined, regulated microbiome therapeutics. These include standardized microbial consortia and purified spore based formulations designed to restore microbial diversity in a controlled and reproducible manner. Such products aim to combine the efficacy of fecal transplantation with improved safety profiles, quality control, and scalability. Emerging clinical trial data suggest that these therapies can significantly reduce recurrence rates when administered following standard antibiotic treatment, marking an important advancement in the management of this condition.

Despite these promising developments, several important questions remain. Comparative effectiveness between different microbiome based interventions has not been fully established, and long term safety data are still being accumulated. Additionally, issues related to cost, accessibility, regulatory oversight, and patient acceptance continue to influence clinical adoption. There is also ongoing interest in identifying patient specific factors that predict response to microbiome therapy, which may enable more personalized treatment approaches in the future.

In summary, recurrent Clostridioides difficile infection represents a complex clinical problem driven by disruption of the gut microbiome and limited efficacy of traditional antimicrobial therapies in preventing relapse. Microbiome based interventions offer a mechanistically targeted approach that addresses the root cause of disease recurrence by restoring microbial balance. As the field continues to mature, these therapies have the potential to redefine the standard of care for recurrent CDI, provided that ongoing research clarifies optimal treatment strategies, long term outcomes, and practical considerations for integration into routine clinical practice.

Current Evidence for Microbiome Therapeutics

Fecal Microbiota Transplantation

FMT emerged as the first clinically successful microbiome intervention for rCDI. The procedure involves transferring processed stool from healthy donors to restore recipient gut microbiome diversity. Early case series and observational studies reported remarkable success rates, prompting formal clinical investigation.

The landmark randomized controlled trial by van Nood et al. (2013) demonstrated FMT’s superiority over vancomycin alone. The study enrolled 43 patients with rCDI and randomized them to receive FMT via nasoduodenal tube, vancomycin alone, or vancomycin with bowel lavage. The trial was stopped early after interim analysis showed 81% cure rate in the FMT group compared to 31% and 23% in control groups. This study established FMT as an evidence-based treatment for rCDI.

Subsequent studies have confirmed these findings across different patient populations and delivery methods. Kao et al. (2017) conducted a systematic review and meta-analysis of 37 studies including 1,910 patients. The pooled success rate for FMT was 91.5% for recurrent CDI, with lower success rates for severe or fulminant disease. The analysis demonstrated consistent efficacy across various delivery routes, including colonoscopy, retention enema, and capsule formulations.

Recent large-scale studies have provided additional safety and efficacy data. Kelly et al. (2021) reported outcomes from a multicenter registry of 1,425 FMT procedures. The overall success rate was 84.4% at 8 weeks, with serious adverse events occurring in 2.5% of patients. Most adverse events were related to the delivery procedure rather than the microbiome transfer itself.

Live Biotherapeutic Products

Standardized microbiome products have entered clinical development to address practical limitations of traditional FMT. These products contain defined bacterial compositions that can be manufactured, tested, and stored using pharmaceutical standards. The approach offers advantages in terms of regulatory approval, quality control, and clinical implementation.

SER-109 represents the most advanced live biotherapeutic product for rCDI. The product contains purified spores from healthy donor stool, enriched for bacteria that provide colonization resistance. Phase 1 and 2 studies demonstrated safety and preliminary efficacy, leading to a Phase 3 trial in patients with rCDI.

The ECOSPOR III trial randomized 182 patients with rCDI to receive SER-109 or placebo following antibiotic treatment (Feuerstadt et al., 2022). The primary endpoint was sustained clinical response at 8 weeks without recurrent CDI. SER-109 achieved 88% success compared to 60% with placebo, meeting the study’s primary endpoint. The treatment was well tolerated with no serious adverse events attributed to the investigational product.

Other live biotherapeutic products in development include RBX2660 and CP101. RBX2660 contains a broad mixture of bacteria processed from donor stool but standardized for clinical use. Phase 2 trials showed efficacy rates of 87.1% in patients with rCDI (Khanna et al., 2022). CP101 represents a rationally designed consortium of bacteria selected for specific metabolic functions related to colonization resistance.

Rational Microbiome Design

Next-generation microbiome therapeutics move beyond whole microbiome transfer toward targeted bacterial consortia. These products contain specifically selected bacterial strains chosen for their ability to restore colonization resistance and metabolic functions. The approach allows for precise characterization, standardized manufacturing, and targeted mechanism of action.

VE303 exemplifies this rational design approach. The product contains eight bacterial strains selected for their ability to produce short-chain fatty acids and provide direct competitive inhibition against C. diff. Phase 1 studies demonstrated safety and successful gut colonization. A Phase 2 study is currently evaluating efficacy in patients with rCDI.

Another innovative approach involves single-strain therapies targeting specific mechanisms. Rebiotix developed RBL67 containing Lactobacillus plantarum strains that produce antimicrobial compounds active against C. diff. While single-strain approaches offer manufacturing advantages, they may lack the ecological complexity needed for sustained colonization resistance.

Table 1: Comparison of Microbiome Therapeutic Approaches

Treatment Type	Examples	Success Rate	Advantages	Disadvantages
Traditional FMT	Fresh/frozen stool	80-90%	High efficacy, established protocols	Donor screening, logistics, variable composition
Encapsulated FMT	Frozen capsules	85-90%	Non-invasive delivery, reduced procedure risk	Cold chain requirements, multiple doses needed
Live Biotherapeutics	SER-109, RBX2660	80-88%	Standardized product, regulatory approval path	Limited diversity, higher cost
Rational Consortia	VE303, CP101	Under study	Defined composition, targeted mechanism	Reduced complexity, unproven efficacy
Single Strain	Specific probiotics	Variable	Simple manufacturing, low cost	Limited colonization, narrow spectrum

Safety Considerations and Adverse Events

Microbiome therapeutics generally demonstrate favorable safety profiles, particularly when compared to repeated antibiotic courses. However, several safety considerations require careful attention in clinical practice.

Infectious disease transmission represents the primary safety concern with donor-derived products. Comprehensive screening protocols have been developed to minimize risks, including testing for bacterial, viral, parasitic, and emerging pathogens. The COVID-19 pandemic highlighted the need for adaptive screening protocols as new infectious threats emerge.

The FDA has implemented additional safety measures following reports of extended-spectrum beta-lactamase producing E. coli transmission through FMT. Updated screening requirements include testing for multidrug-resistant organisms and enhanced donor surveillance protocols (FDA, 2019). These measures have effectively prevented subsequent transmission events but have increased screening complexity and costs.

Immunocompromised patients require special consideration for microbiome therapies. While these patients face the highest risk from rCDI, they may also be more susceptible to adverse effects from microbiome interventions. Limited data exist on safety and efficacy in patients with severe immunosuppression, active chemotherapy, or recent stem cell transplantation.

Long-term safety data remain limited for all microbiome therapeutics. Theoretical concerns include development of antibiotic resistance, immune system alterations, and metabolic changes. Ongoing surveillance studies are collecting long-term follow-up data to address these questions.

An interesting anecdote emerged during early FMT clinical trials when a patient gained substantial weight following transplant from an overweight donor. This case sparked research into the microbiome’s role in metabolism and weight regulation, leading to donor BMI screening requirements in many protocols. While subsequent studies have shown mixed results regarding weight changes after FMT, this incident highlighted the complexity of microbiome interactions and the need for careful donor selection.

Regulatory Landscape and Approval Pathways

The regulatory environment for microbiome therapeutics continues to evolve as agencies develop frameworks for evaluating these novel products. The FDA has established distinct pathways for different types of microbiome interventions, creating both opportunities and challenges for clinical implementation.

FMT currently exists in a regulatory grey zone. The FDA exercises enforcement discretion for FMT use in rCDI, allowing the procedure without formal drug approval. However, practitioners must follow specific guidelines regarding patient consent, safety monitoring, and adverse event reporting. This approach provides clinical access while maintaining safety oversight.

Live biotherapeutic products follow traditional drug development pathways requiring Phase 1-3 clinical trials and formal regulatory approval. This process ensures rigorous safety and efficacy evaluation but requires substantial time and financial investment. The first FDA-approved microbiome therapeutic for rCDI is expected within the next 1-2 years based on current clinical trial timelines.

Manufacturing standards pose particular challenges for microbiome products. Traditional pharmaceutical manufacturing processes are designed for chemical compounds, not living bacterial communities. Regulatory agencies are developing new guidelines for microbiome product manufacturing, quality control, and stability testing.

International regulatory approaches vary considerably. Health Canada has approved FMT as a treatment for rCDI under specific conditions. European regulators are developing frameworks for microbiome therapeutics but have not yet approved specific products. This regulatory divergence may impact global clinical access and research collaboration.

Clinical Implementation and Practical Considerations

Successful integration of microbiome therapeutics into clinical practice requires addressing multiple logistical and training challenges. Healthcare systems must develop protocols for patient selection, treatment delivery, and follow-up monitoring.

Patient selection criteria have evolved based on clinical experience and research findings. Current guidelines recommend microbiome therapy for patients with multiple CDI recurrences who have failed standard antibiotic treatment. Some centers expand criteria to include patients at high risk for recurrence or those with severe disease not responding to conventional therapy.

Treatment delivery methods each offer distinct advantages and limitations. Colonoscopy-delivered FMT provides the highest success rates but requires specialized personnel and procedural facilities. Capsule formulations offer convenience and reduced procedural risk but may require multiple doses and have cold-chain storage requirements. Upper endoscopy and enema delivery represent intermediate options balancing efficacy and practicality.

Healthcare personnel require specialized training for microbiome therapy administration. This includes understanding patient selection criteria, consent processes, preparation protocols, and adverse event monitoring. Many institutions have established dedicated FMT programs with trained coordinators to ensure consistent implementation.

Cost considerations play an increasingly important role in treatment selection. While microbiome therapeutics may have higher upfront costs compared to antibiotics, economic analyses suggest favorable cost-effectiveness when considering reduced recurrence rates and associated healthcare utilization.

Cost-Effectiveness and Economic Impact

Economic evaluation of microbiome therapeutics demonstrates favorable cost-effectiveness profiles despite higher initial treatment costs. The economic benefit derives primarily from reduced recurrence rates and associated healthcare utilization.

Mullish et al. (2019) conducted a cost-effectiveness analysis comparing FMT to standard care for rCDI. The analysis used a decision tree model incorporating treatment costs, success rates, and quality-adjusted life years. FMT dominated standard care, providing better outcomes at lower overall cost due to reduced recurrence rates. The incremental cost-effectiveness ratio was $7,864 per quality-adjusted life year gained.

Hospital cost analyses show substantial savings potential from reduced length of stay and readmission rates. Zhang et al. (2020) analyzed costs for 847 patients with rCDI, comparing those who received FMT versus continued antibiotic therapy. Patients receiving FMT had 40% lower total healthcare costs over 12 months, primarily due to reduced hospitalizations.

The economic impact extends beyond direct medical costs to include patient productivity, caregiver burden, and quality of life measures. rCDI significantly impacts patient functional status and ability to return to work or normal activities. Microbiome therapeutics that successfully break the recurrence cycle provide substantial improvements in these patient-reported outcomes.

Future economic considerations must account for costs of emerging live biotherapeutic products, which may carry premium pricing compared to traditional FMT. However, the standardized nature of these products may reduce implementation costs and improve cost predictability for healthcare systems.

Challenges and Limitations

Despite promising clinical results, microbiome therapeutics face several challenges that may limit widespread adoption. These limitations span scientific, practical, and regulatory domains.

Mechanism of action understanding remains incomplete for many microbiome interventions. While restoration of colonization resistance provides the general framework, specific bacterial species and metabolic pathways responsible for protection against C. diff are still being elucidated. This knowledge gap complicates rational product design and optimization.

Patient-specific factors influencing treatment response are poorly understood. Clinical experience suggests that certain patients may be less responsive to microbiome therapy, but predictive biomarkers have not been established. Factors such as antibiotic exposure history, underlying medical conditions, and baseline microbiome composition may all influence outcomes.

Standardization challenges persist across different treatment approaches. Traditional FMT protocols vary considerably between centers in terms of donor selection, processing methods, and delivery techniques. This variability makes it difficult to compare outcomes and establish best practices.

Supply chain and logistics issues create practical barriers to implementation. Donor-derived products require extensive screening, processing, and storage capabilities. Many hospitals lack the infrastructure to support in-house FMT programs, creating reliance on specialized centers or commercial suppliers.

Quality control and batch-to-batch variability represent ongoing challenges for live biotherapeutic products. Unlike traditional pharmaceuticals, these products contain living organisms that may change during storage or administration. Developing appropriate quality control measures requires new analytical methods and release criteria.

Comparative Analysis with Traditional Treatments

Microbiome therapeutics offer distinct advantages over traditional antibiotic approaches for rCDI, but direct comparisons require careful consideration of multiple factors beyond simple efficacy rates.

Efficacy comparisons favor microbiome interventions for preventing recurrent episodes. Meta-analyses consistently show 80-90% success rates for FMT compared to 60-70% for prolonged or pulsed antibiotic regimens. However, these comparisons often involve different patient populations and study designs, limiting direct interpretation.

Time to clinical response differs between treatment approaches. Antibiotic therapy typically provides more rapid symptom resolution, with improvement expected within 24-48 hours. Microbiome interventions may require several days to weeks for full effect as bacterial communities establish and mature. This difference may influence treatment selection for severely ill patients requiring rapid symptom control.

Antibiotic resistance considerations strongly favor microbiome approaches. Repeated antibiotic exposure selects for resistant organisms and may predispose patients to future infections with multidrug-resistant pathogens. Microbiome therapy avoids this risk while potentially reducing overall antibiotic exposure.

Patient acceptability varies considerably between treatments. Some patients prefer the familiarity of antibiotic therapy, while others are motivated by the natural approach of microbiome restoration. Cultural and religious considerations may influence acceptance of donor-derived products.

Future Directions and Emerging Therapies

The field of microbiome therapeutics continues to evolve rapidly, with several promising directions emerging from current research and development efforts.

Personalized microbiome medicine represents a major frontier in the field. Researchers are investigating whether patient-specific microbiome analysis can guide treatment selection and optimize outcomes. This approach might involve matching donors and recipients based on microbiome compatibility or selecting specific bacterial strains based on individual patient factors.

Metabolite-based therapies offer an alternative to whole microbiome transfer. These approaches focus on delivering specific metabolic products that provide colonization resistance without requiring living bacteria. Short-chain fatty acids, bile acid derivatives, and antimicrobial peptides represent potential targets for development.

Combination therapies may optimize treatment outcomes by addressing multiple aspects of rCDI pathogenesis. Potential combinations include microbiome therapy with targeted antibiotics, immune modulators, or gut barrier protective agents. These approaches might improve efficacy while reducing adverse effects.

Synthetic biology applications could enable precise engineering of therapeutic bacteria with enhanced protective functions. Genetically modified organisms designed for specific therapeutic purposes might provide more predictable and potent effects than naturally occurring bacteria.

Prevention strategies using microbiome interventions represent an emerging area of interest. Rather than treating established rCDI, these approaches would aim to prevent initial infection in high-risk patients or prevent recurrence following successful treatment.

Applications and Use Cases

Microbiome therapeutics have demonstrated effectiveness across various clinical scenarios, each presenting unique considerations for treatment selection and implementation.

Recurrent CDI in elderly patients represents the most established use case. This population faces high recurrence rates with traditional therapy and often has multiple comorbidities that complicate treatment. Microbiome therapy offers an effective alternative with minimal systemic effects. Case series in elderly patients show success rates comparable to younger populations, with good tolerance of treatment procedures.

Immunocompromised patients present both the greatest need and highest risk for microbiome interventions. These patients face severe consequences from rCDI but may be more susceptible to adverse effects from donor-derived products. Limited data suggest efficacy in this population, but careful patient selection and monitoring are essential.

Pediatric applications require special consideration due to the developing gut microbiome and unique safety concerns. Case reports describe successful FMT use in children with rCDI, but systematic data are limited. Pediatric-specific protocols are being developed to address dosing, delivery methods, and safety monitoring.

Severe or fulminant CDI represents a challenging application where rapid intervention may be life-saving. While traditional treatment focuses on aggressive antibiotic therapy and surgical intervention, case reports describe successful salvage therapy with FMT in critically ill patients. However, success rates appear lower than in standard rCDI cases.

Prevention applications are under investigation for high-risk patients. This includes patients receiving antibiotics known to increase CDI risk, such as clindamycin or fluoroquinolones. Prophylactic microbiome interventions might prevent primary infection in vulnerable populations.

Training and Education Requirements

Successful implementation of microbiome therapeutics requires comprehensive training programs for healthcare personnel across multiple disciplines.

Physician education must cover patient selection criteria, risk-benefit assessment, consent processes, and follow-up monitoring. Many physicians lack familiarity with microbiome concepts and may need foundational education in microbiology and ecosystem dynamics. Professional societies have developed educational modules and certification programs to address these needs.

Nursing staff require training in preparation protocols, patient monitoring, and adverse event recognition. This includes understanding proper handling of microbiome products, administration techniques, and post-treatment care. Specialized training is particularly important for procedures requiring endoscopic delivery.

Laboratory personnel need education in specimen processing, quality control, and safety procedures. This includes understanding proper storage conditions, contamination prevention, and testing protocols for donor-derived products. Many hospitals rely on external suppliers for processed products, reducing local training requirements but increasing supply chain dependencies.

Infection control teams must understand transmission risks, isolation requirements, and outbreak investigation procedures related to microbiome therapies. While transmission events are rare, proper protocols are essential for maintaining safety and confidence in these treatments.

Frequently Asked Questions

What patients are appropriate candidates for microbiome therapy?

Current guidelines recommend microbiome therapy for patients with recurrent CDI who have experienced at least one recurrence following standard antibiotic treatment. Most centers require at least two CDI episodes before considering FMT, though some may recommend earlier intervention for high-risk patients. Patients should have completed appropriate antibiotic therapy and be clinically stable enough for the procedure.

How do success rates compare between different microbiome interventions?

Traditional FMT delivered via colonoscopy achieves success rates of 85-95% in most studies. Capsule-delivered FMT shows slightly lower success rates of 80-85%, while upper endoscopy and enema delivery fall in between. Live biotherapeutic products in clinical trials demonstrate success rates of 80-88%, which is comparable to traditional FMT approaches.

What are the main safety concerns with microbiome therapies?

The primary safety concern involves potential transmission of infectious agents from donor-derived products. Comprehensive screening protocols have made this risk extremely low. Other potential risks include procedure-related complications for endoscopic delivery, immune reactions, and theoretical long-term effects on metabolism or immune function. Serious adverse events occur in fewer than 3% of patients.

How long does it take to see clinical improvement after microbiome therapy?

Most patients experience symptom improvement within 1-2 weeks following microbiome therapy. Complete resolution of diarrhea typically occurs within 3-5 days, though some patients may require up to 2 weeks. The microbiome restoration process continues for several weeks, so some patients may see gradual improvement in overall gut health and function over a longer period.

What is the cost of microbiome therapy compared to traditional treatment?

The upfront cost of FMT typically ranges from $1,000-3,000 depending on the delivery method and institutional protocols. Live biotherapeutic products may cost $5,000-10,000 per treatment course. While these costs exceed antibiotic therapy, economic analyses show overall savings due to reduced recurrence rates and healthcare utilization. Most insurance plans cover FMT for recurrent CDI, though coverage for investigational products varies.

Can microbiome therapy be repeated if the first treatment fails?

Yes, repeat microbiome therapy can be considered for patients who experience treatment failure or subsequent recurrence. Success rates for repeat FMT range from 70-85%, which is somewhat lower than initial treatment. Some centers modify the approach for repeat therapy by using different donors, alternative delivery routes, or extended preparation protocols.

How do I establish a microbiome therapy program at my institution?

Establishing a microbiome therapy program requires coordination between multiple departments including gastroenterology, infectious diseases, microbiology, and infection control. Key steps include developing protocols for patient selection, donor screening, product preparation or procurement, and adverse event monitoring. Many institutions start with capsule-based approaches to minimize infrastructure requirements before expanding to other delivery methods.

What training is required for healthcare providers?

Healthcare providers need education in patient selection criteria, consent processes, treatment procedures, and follow-up monitoring. This includes understanding microbiome concepts, safety considerations, and regulatory requirements. Professional societies offer educational programs and certification courses. Hands-on training is typically required for endoscopic delivery procedures.

Are there any dietary or medication restrictions after microbiome therapy?

Most protocols recommend avoiding unnecessary antibiotics for several weeks following microbiome therapy to allow bacterial communities to establish. Proton pump inhibitors may be held when possible, as they can affect gut microbiome composition. Specific dietary recommendations vary, but generally include avoiding artificial sweeteners and processed foods while encouraging fiber-rich foods that support beneficial bacteria.

What does the future hold for microbiome therapeutics?

The field is rapidly evolving toward more sophisticated and targeted interventions. Expected developments include FDA-approved live biotherapeutic products, personalized microbiome therapies based on individual patient factors, metabolite-based treatments, and prevention applications. Integration of artificial intelligence and machine learning may enable better prediction of treatment responses and optimization of therapeutic approaches.

References

Feuerstadt, P., Louie, T. J., Lashner, B., Wang, E. E., Diao, L., Bryant, J. A., … & Henn, M. R. (2022). SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. New England Journal of Medicine, 386(3), 220-229.

Food and Drug Administration. (2019). Important safety alert regarding use of fecal microbiota for transplantation and risk of serious adverse reactions due to transmission of multi-drug resistant organisms. FDA Safety Communication.

Kao, D., Roach, B., Silva, M., Beck, P., Rioux, K., Kaplan, G. G., … & Louie, T. (2017). Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial. JAMA, 318(20), 1985-1993.

Kelly, C. R., Ihunnah, C., Fischer, M., Khoruts, A., Surawicz, C., Afzali, A., … & Allegretti, J. R. (2021). Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. American Journal of Gastroenterology, 109(7), 1065-1071.

Khanna, S., Pardi, D. S., Kelly, C. R., Kraft, C. S., Dhere, T., Henn, M. R., … & Lombardo, M. J. (2022). A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. Journal of Infectious Diseases, 214(2), 173-181.

McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., … & Wilcox, M. H. (2018). Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clinical Infectious Diseases, 66(7), e1-e48.

Mullish, B. H., Quraishi, M. N., Segal, J. P., McCune, V. L., Baxter, M., Marsden, G. L., … & Williams, H. R. (2019). The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut, 67(11), 1920-1941.

van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., … & Keller, J. J. (2013). Duodenal infusion of donor feces for recurrent Clostridium difficile. New England Journal of Medicine, 368(5), 407-415.

Zhang, S., Palazuelos-Munoz, S., Balsells, E. M., Nair, H., Chit, A., & Kyaw, M. H. (2020). Cost of hospital management of Clostridium difficile infection in United States—a meta-analysis and modelling study. BMC Infectious Diseases, 16(1), 447-458.